aTyr Pharma (NASDAQ:ATYR) Earns Market Perform Rating from Leerink Partners

by · The Markets Daily

aTyr Pharma (NASDAQ:ATYR – Get Free Report)‘s stock had its “market perform” rating reaffirmed by investment analysts at Leerink Partners in a research note issued to investors on Monday, MarketBeat reports.

ATYR has been the subject of several other research reports. Wall Street Zen cut shares of aTyr Pharma from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. Cantor Fitzgerald lowered shares of aTyr Pharma from an “overweight” rating to a “neutral” rating in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th. Jefferies Financial Group raised their price target on shares of aTyr Pharma from $9.00 to $17.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. Finally, Wells Fargo & Company increased their price objective on shares of aTyr Pharma from $17.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.25.

Read Our Latest Stock Analysis on ATYR

aTyr Pharma Stock Down 83.3%

ATYR stock traded down $5.02 during trading on Monday, hitting $1.01. 153,796,609 shares of the stock traded hands, compared to its average volume of 4,697,416. aTyr Pharma has a one year low of $1.00 and a one year high of $7.29. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a 50 day simple moving average of $5.28 and a 200 day simple moving average of $4.37.

aTyr Pharma (NASDAQ:ATYR – Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.04). On average, equities research analysts expect that aTyr Pharma will post -0.91 EPS for the current year.

Hedge Funds Weigh In On aTyr Pharma

A number of hedge funds have recently bought and sold shares of ATYR. Octagon Capital Advisors LP raised its stake in aTyr Pharma by 294.7% in the 1st quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company’s stock valued at $10,727,000 after acquiring an additional 2,652,000 shares during the period. Erste Asset Management GmbH purchased a new stake in aTyr Pharma in the first quarter worth approximately $1,812,000. Bank of America Corp DE purchased a new stake in aTyr Pharma in the fourth quarter worth approximately $330,000. Jane Street Group LLC purchased a new stake in shares of aTyr Pharma during the fourth quarter valued at approximately $720,000. Finally, Millennium Management LLC bought a new position in shares of aTyr Pharma during the fourth quarter valued at approximately $1,332,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

(Get Free Report)

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Recommended Stories